摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S)-2-{4-[(2-aminobenzoyl)amino]benzyl}-N,N-diethyl-N'-(2-naphthylsulfonyl)malonamide | 1094195-58-0

中文名称
——
中文别名
——
英文名称
(2S)-2-{4-[(2-aminobenzoyl)amino]benzyl}-N,N-diethyl-N'-(2-naphthylsulfonyl)malonamide
英文别名
(2S)-2-[[4-[(2-aminobenzoyl)amino]phenyl]methyl]-N,N-diethyl-N'-naphthalen-2-ylsulfonylpropanediamide
(2S)-2-{4-[(2-aminobenzoyl)amino]benzyl}-N,N-diethyl-N'-(2-naphthylsulfonyl)malonamide化学式
CAS
1094195-58-0
化学式
C31H32N4O5S
mdl
——
分子量
572.685
InChiKey
YZHBIJMUIYTKOM-HHHXNRCGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    41
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    147
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
    申请人:National Cerebral and Cardiovascular Center
    公开号:EP3127554A1
    公开(公告)日:2017-02-08
    Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
    本文提供了一种用于抑制或预防癌等恶性肿瘤转移的新型药物、一种用于抑制或预防恶性肿瘤转移的新型治疗或预防方法等。该药物包括作为活性成分的非肽类血管紧张素 2 型受体激动剂。在该药物中,非肽类血管紧张素 2 型受体激动剂可以是磺酰丙二酰胺化合物等。该药物可以是与抗癌剂和/或抗肿瘤剂联合使用的药物。
  • Medicament for suppressing malignant tumor metastasis
    申请人:NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    公开号:US10071099B2
    公开(公告)日:2018-09-11
    Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
    本文提供了一种用于抑制或预防癌等恶性肿瘤转移的新型药物、一种用于抑制或预防恶性肿瘤转移的新型治疗或预防方法等。该药物包括作为活性成分的非肽类血管紧张素 2 型受体激动剂。在该药物中,非肽类血管紧张素 2 型受体激动剂可以是磺酰丙二酰胺化合物等。该药物可以是与抗癌剂和/或抗肿瘤剂联合使用的药物。
  • NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP2172450B9
    公开(公告)日:2014-10-08
  • MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
    申请人:NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    公开号:US20170014419A1
    公开(公告)日:2017-01-19
    Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
  • MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY
    申请人:National Cerebral and Cardiovascular Center
    公开号:US20180280326A1
    公开(公告)日:2018-10-04
    The present invention provides a novel medicament for preventing or inhibiting acute kidney injury, the medicament comprising, as an active ingredient, an angiotensin II receptor type 2 agonist or a pharmacologically acceptable salt thereof, and being used for treatment or prevention of acute kidney injury. Also, the present invention provides a novel method for preventing or inhibiting acute kidney injury, the method comprising administering, to a patient, an effective amount of an angiotensin II receptor type 2 agonist or a pharmacologically acceptable salt thereof in combination with an anticancer agent and/or an antitumor agent.
查看更多